Related Experiment Videos
Intravenous glycoprotein IIb/IIIa inhibition in non-ST segment elevation acute coronary syndromes
1Department of Cardiology, Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, OH 44195, USA.
Insights
Glycoprotein IIb/IIIa inhibitors show varied efficacy and increased adverse events in acute coronary syndromes. Further research clarifies their complex role in managing coronary instability.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Glycoprotein IIb/IIIa inhibitors are recommended for non-ST segment elevation acute coronary syndromes.
- Their clinical use in acute coronary syndromes remains debated due to inconsistent trial results.
Purpose of the Study:
- To re-examine clinical trial data on glycoprotein IIb/IIIa inhibition.
- To explain the heterogeneity in clinical evidence and adverse events.
- To refine understanding of glycoprotein IIb/IIIa antagonist therapy and its clinical application.
Main Methods:
- Review of randomized placebo-controlled trials.
- Analysis of clinical trial data in light of new evidence.
- Consideration of pharmacokinetic characteristics of glycoprotein IIb/IIIa inhibitors.
Main Results:
- Uniform efficacy of glycoprotein IIb/IIIa inhibitors has not been demonstrated in trials.
- Some trials show a concerning excess of adverse events.
- Heterogeneity in clinical evidence is not fully explained but may relate to drug properties.
Conclusions:
- Evolving insights into glycoprotein IIb/IIIa inhibition and pharmacokinetics aid interpretation of trial results.
- Optimal clinical application of these agents requires consideration of recent evidence.
- Further understanding may improve management of coronary instability.
Abstract:
Over recent years, substantial clinical trial evidence regarding glycoprotein IIb/IIIa inhibition for the medical management of non-ST segment elevation acute coronary syndromes has been compiled. Despite being recently advocated for the management of coronary instability within widely accepted guidelines, its use among patients presenting with acute coronary syndromes remains somewhat contentious. Within randomized placebo-controlled trials, uniform efficacy with the glycoprotein IIb/IIIa inhibitors has not been shown, whereas a disturbing excess in adverse events is evident within some trials. Currently, the basis for this heterogeneity of clinical evidence has not been adequately explained. However, evolving insights from clinical trials and basic research have further refined our understanding of glycoprotein IIb/IIIa antagonist therapy and the potential effects beyond the inhibition of the fibrinogen receptor. Likewise, appreciation of the pharmacokinetic characteristics of these agents provides putative explanations for the diverse findings of the randomized trials. Reexamination of the clinical trial data in light of this recent evidence provides a basis for interpreting the marginal results of glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Consideration of these factors may facilitate the optimal clinical application of this class of agents to the management of coronary instability.